Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
Date:8/5/2014

of a combination of deuterium modified dextromethorphan (an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin transporter (SERT) and norepinephrine (NET) transporter) and ultra-low dose quinidine (a CYP2D6 enzyme inhibitor). Incorporation of deuterium into specific positions of the dextromethorphan molecule strengthens the chemical bonds and reduces susceptibility to enzyme cleavage and first pass metabolism, but without altering its pharmacology. AVP-786 is an investigational drug not approved by the FDA.

About AVP-923AVP-923 is a combination of two well-characterized compounds, the active CNS ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin transporter (SERT) and norepinephrine (NET) transporter) plus low-dose quinidine sulfate (a CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of dextromethorphan. AVP-923 is being studied in several ongoing company sponsored Phase II clinical trials including agitation in Alzheimer's disease, levodopa-induced dyskinesia in Parkinson's disease, and multiple investigator initiated studies. AVP-923 is an investigational drug not approved by the FDA. AVP-923 at the 20/10 mg dose strength is approved by the FDA for the treatment of pseudobulbar affect (PBA) and marketed under the trade name NUEDEXTA (see description below). AVP-923 is an investigational drug not approved by the FDA for any uses other than PBA.

About NUEDEXTANUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

N
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Avanir Pharmaceuticals To Present at Three Conferences In May
2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... ANGELES, May 1, 2015  CytRx Corporation (CYTR), ... oncology, today reported financial results for the three ... overview of recent accomplishments and upcoming milestones for ... several milestones in the early months of 2015, ... clinical trial of aldoxorubicin in patients with soft ...
(Date:5/1/2015)... 2015 The Institute for Healthcare Advancement (IHA) ... winners. The IHA Health Literacy Awards aim to encourage, ... the practice of educating or empowering organizations to deliver ... in three categories: innovative programs, published materials and research. ... award. In the area of innovative programs, ...
(Date:5/1/2015)... SUNNYVALE, Calif., May 1, 2015 Pharmacyclics, Inc. ... results for the quarter ended March 31, 2015, as ... merger with AbbVie Inc., no conference call will be held. ... the quarter ended March 31, 2015 increased to $206 ... 31, 2014. , Worldwide IMBRUVICA ® (ibrutinib) ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Institute for Healthcare Advancement Announces 2015 Award Winners 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25
... HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA), a ... consummated two separate transactions to acquire all the online ... medications, diabetics supplies, and medical equipment, and merge with ... "The combination will bring together two companies committed ...
... and INGELHEIM, Germany, Feb. 15, 2011 Pfenex ... the Pfenex Expression Technology™ platform and Boehringer Ingelheim ... leader in biopharmaceutical contract development and manufacture, announced ... agreement. It provides Boehringer Ingelheim with non-exclusive access ...
Cached Medicine Technology:HealthWarehouse.com Acquires Online Division of Hocks Pharmacy 2Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™ 2Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™ 3
(Date:5/2/2015)... 2015 We are pleased to announce ... Center as one of the Top Workplaces of 2015. ... addiction treatment field for their ethics and standards of ... to continue their educational efforts. The Delray Recovery Center ... forgetting their purpose – to help individuals heal from ...
(Date:5/2/2015)... East Liverpool, Ohio (PRWEB) May 02, 2015 ... of East Liverpool City Hospital (ELCH) gathered to celebrate ... direction of River Valley Health Partners (RVHP), had zero ... and zero urinary catheter associated infections. ELCH was also ... , The management team at ELCH credited the ...
(Date:5/2/2015)... 02, 2015 As a nonsurgical ... of the face, neck and décolleté, radiofrequency energy ... real potential for the success of vulvovaginal rejuvenation. ... Clinical Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory ... concluded that ThermiGyn’s temperature controlled radio frequency, specifically ...
(Date:5/2/2015)... 02, 2015 With the success that Veatch ... proud to welcome Neida Miranda and Alex Shields to the ... has over 41 years of combined experience working with dentists ... the dental field for 8 years. She was certified ... Texas. Customer service, positive attitude and showing the importance of ...
(Date:5/1/2015)... and Caicos Islands, BWI (PRWEB) May 02, 2015 ... new website! It is http://www.thevenetiangracebay.com , and ... and it incorporates the stunning white and attractive turquoise ... a study of Google, sixty seven percent of leisure ... The study showed that smartphones were used in the ...
Breaking Medicine News(10 mins):Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2
... Dear is not happy with the amount of diabetic patients ... only 60% of diabetic patients // had signed up ... state, funded program. , ,The President is not happy ... diabetics is not properly monitored it could lead to complications ...
... spread across the walls of a patient's room have ... diseases, hypertension and rheumatic complaints, a study says.//,A study ... patients kept in medicated rooms were cured in shorter ... ,The study involved 36 patients, of whom 19 were ...
... result in bring on common cold symptoms, says a new ... conventional wisdom of mothers about cold. // ,Mothers often advice ... with wet hair. Since the early 1960s, doctors generally doubted ... ABC News. , ,Ron Eccles, a professor at Cardiff ...
... are planning strategies to overcome from the crisis if ... an epidemic of bird flu strikes Japan it could ... Government is planning to have a cabinet meeting next ... different Government officials and cabinet ministers to prepare preventive ...
... medical officer, has attacked the health profession for complacency in ... is now a “biological inevitability”. //, ,Last week Donaldson ... the royal colleges, to emphasize that the disease could kill ... as a joke. , He is planning to issue ...
... present the first proof that simple exposure to cold weather ... if your mother always warned you to wrap up warm ... had a point. , ,Scientists say they have the ... cold and catching one. , ,Their study findings will ...
Cached Medicine News:Health News:Now medicated coir to cure ailments 2Health News:Doctors attacked for complacency against pandemic threat 2Health News:Scientist affirm mother’s advice 2